Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Average Recommendation of “Reduce” from Analysts

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been given an average recommendation of “Reduce” by the eight analysts that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $18.8571.

Several research firms have recently weighed in on IART. BMO Capital Markets began coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price on the stock. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. UBS Group began coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 target price for the company. Truist Financial lifted their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Finally, Wells Fargo & Company increased their target price on shares of Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th.

Integra LifeSciences Stock Down 0.3%

Shares of NASDAQ:IART traded down $0.06 during trading on Monday, hitting $16.68. The company’s stock had a trading volume of 19,893 shares, compared to its average volume of 883,356. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $20.49. The stock’s 50-day moving average price is $17.99 and its two-hundred day moving average price is $14.07. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. The company has a market capitalization of $1.30 billion, a PE ratio of -185.30, a PEG ratio of 1.41 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The company had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, sell-side analysts expect that Integra LifeSciences will post 2.46 EPS for the current year.

Institutional Trading of Integra LifeSciences

A number of institutional investors and hedge funds have recently made changes to their positions in IART. Osaic Holdings Inc. raised its position in Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the last quarter. State of Tennessee Department of Treasury boosted its position in shares of Integra LifeSciences by 7.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock worth $332,000 after purchasing an additional 1,964 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after purchasing an additional 1,975 shares in the last quarter. Capital Fund Management S.A. raised its position in shares of Integra LifeSciences by 5.7% during the third quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after purchasing an additional 1,997 shares during the period. Finally, Global Retirement Partners LLC acquired a new position in shares of Integra LifeSciences in the fourth quarter valued at approximately $25,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.